Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2024 | $36.00 | Buy | D. Boral Capital |
| 11/14/2024 | $9.00 | Buy | Rodman & Renshaw |
| 12/8/2022 | $12.00 → $2.00 | Buy → Neutral | UBS |
| 11/8/2022 | $8.00 → $3.00 | Neutral → Underperform | BofA Securities |
| 6/8/2022 | $12.00 → $4.00 | Buy → Neutral | BofA Securities |
| 10/19/2021 | $19.00 → $12.00 | Buy | HC Wainwright & Co. |
| 10/8/2021 | Neutral → Underweight | JP Morgan | |
| 10/6/2021 | $32.00 → $19.00 | Buy | HC Wainwright & Co. |
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8 million, or $1.73 per share in the prior year period. At September 30, 2024, we had $123.2 million of cash and short-term investments available for operations and debt servicing,
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2024, which include: Net loss for the second quarter of 2024 was $56.0 million, or $0.97 per share, compared to a net loss of $37.3 million, or $0.59 per share for the second quarter of 2023.
D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00
Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00
UBS downgraded Omeros from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
8-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
– Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients – Results of statistical analyses of survival in narsoplimab-treated expanded access program (EAP) TA-TMA patients compared to similarly at-risk external control registry patients were consistent with those of previously reported analyses comparing survival between narsoplimab-treated OMS721-TMA-001 pivotal trial and external control registry patients The analyses conducted on the combined population of the 49 previously untreated high-risk adult (at least 16 years of age) allogeneic-transplan
Omeros Corporation (NASDAQ:OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research. The following materials are now available at www.investor.omeros.com/presentations: The slides accompanying a presentation by Michelle Schoettler, M.D., Assistant Professor of Pediatric Oncology and Hematopoietic Cellular Therapy at Emory University, of overall survival data from 128 allogeneic transplant patients with TA-TMA treated with narsopli
– Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA – Sensitivity analyses support the results of the primary endpoint analysis, with representative sensitivity analyses demonstrating: Narsoplimab-treated patients had an over 2-fold reduction (hazard ratio = 0.42 [95% confidence interval: 0.21, 0.83]) to an over 4-fold reduction (hazard ratio = 0.24 [95% confidence interval: 0.13, 0.47] in risk of mortality P-values ranging from 0.0124 to < 0.00001 The primary endpoint analysis, previously reported on December 19, 2024, showed an over 3-fold reduction in risk of mortality (haz
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G - OMEROS CORP (0001285819) (Subject)
3 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch